Medicine - Hematology and Medical Oncology

Research output

Research output per year 1949 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

• 295025 Citations
• 233 h-index
• 4032 Article
• 685 Review article
• 251 Letter
• 203 Comment/debate
• 303 More
  • 131 Chapter
  • 100 Editorial
  • 41 Short survey
  • 12 Conference contribution
  • 6 Foreword/postscript
  • 5 Book
  • 5 Paper
  • 3 Conference article

Research output per year

Research output per year

Search results

• 2023

  An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

  Qin, A., Urbanski, R. W., Yu, L., Ahmed, T. & Mascarenhas, J., 19 Jan 2023, In: Frontiers in Oncology. 13, 1109866.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Polycythemia Vera 100%
  • Proline 82%
  • History 58%
  • Clinical Trials 50%
  • Neoplasms 49%

• An MDM2 degrader for treatment of acute leukemias

  Marcellino, B. K., Yang, X., Ümit Kaniskan, H., Brady, C., Chen, H., Chen, K., Qiu, X., Clementelli, C., Herschbein, L., Li, Z., Elghaity-Beckley, S., Arandela, J., Kelly, B., Hoffman, R., Liu, J., Xiong, Y., Jin, J. & Shih, A. H., Feb 2023, In: Leukemia. 37, 2, p. 370-378 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia 100%
  • venetoclax 97%
  • Proteolysis 86%
  • Acute Myeloid Leukemia 58%
  • Azacitidine 40%

• Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis

  CCC-GEM Project Research Consortium & OSCCAR Consortium, Apr 2023, In: Gastroenterology. 164, 4, p. 619-629 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Ulcerative Colitis 100%
  • Integrins 95%
  • Autoantibodies 93%
  • Biomarkers 66%
  • Colitis 13%

• A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma

  Derman, B. A., Chari, A., Zonder, J., Major, A., Stefka, A. T., Jiang, K., Karrison, T., Jasielec, J. & Jakubowiak, A., 2023, (Accepted/In press) In: European Journal of Haematology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • selinexor 100%
  • carfilzomib 85%
  • Multiple Myeloma 53%
  • Dexamethasone 49%
  • Maximum Tolerated Dose 47%

• A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19

  Bowdish, M. E., Barkauskas, C. E., Overbey, J. R., Gottlieb, R. L., Osman, K., Duggal, A., Marks, M. E., Hupf, J., Fernandes, E., Leshnower, B. G., Golob, J. L., Iribarne, A., Rassias, A. J., Moquete, E. G., O'Sullivan, K., Chang, H. L., Williams, J. B., Parnia, S., Patel, N. C., Desai, N. D., & 17 othersVekstein, A. M., Hollister, B. A., Possemato, T., Romero, C., Hou, P. C., Burke, E., Hayes, J., Grossman, F., Itescu, S., Gillinov, M., Pagani, F. D., O'Gara, P. T., Mack, M. J., Smith, P. K., Bagiella, E., Moskowitz, A. J. & Gelijns, A. C., 1 Feb 2023, In: American Journal of Respiratory and Critical Care Medicine. 207, 3, p. 261-270 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Severe Acute Respiratory Syndrome 100%
  • Adult Respiratory Distress Syndrome 85%
  • Mesenchymal Stem Cells 69%
  • Mechanical Ventilators 23%
  • Clinical Trials Data Monitoring Committees 17%
  1 Scopus citations

• Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c⁺ B cells

  Malle, L., Patel, R. S., Martin-Fernandez, M., Stewart, O. J., Philippot, Q., Buta, S., Richardson, A., Barcessat, V., Taft, J., Bastard, P., Samuels, J., Mircher, C., Rebillat, A. S., Maillebouis, L., Vilaire-Meunier, M., Tuballes, K., Rosenberg, B. R., Trachtman, R., Casanova, J. L., Notarangelo, L. D., & 3 othersGnjatic, S., Bush, D. & Bogunovic, D., 9 Mar 2023, In: Nature. 615, 7951, p. 305-314 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Down Syndrome 100%
  • Autoimmunity 93%
  • B-Lymphocytes 74%
  • Cytokines 59%
  • T-Lymphocytes 59%
  1 Scopus citations

• Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support

  Mouhieddine, T. H., Moshier, E., Thibaud, S., Puliafito, B., Rattu, M., Jakubowski, R., Sanchez, L., Rossi, A., Rodriguez, C., Richard, S., Cho, H. J., Parekh, S., Chari, A., Steinberg, A. & Richter, J., Jan 2023, In: Bone Marrow Transplantation. 58, 1, p. 80-86 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Melphalan 100%
  • Carmustine 72%
  • Stem Cells 60%
  • Clinical Trials 53%
  • Drug Therapy 48%

• Cannabis Use and CKD: Epidemiological Associations and Mendelian Randomization

  Dellepiane, S., Paranjpe, I., Rajagopal, M., Kamat, S., O'Hagan, R., Gulamali, F., Rein, J. L., Charney, A. W., Do, R., Coca, S., Glicksberg, B. S. & Nadkarni, G. N., Feb 2023, In: Kidney Medicine. 5, 2, 100582.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cannabis 100%
  • Random Allocation 92%
  • Chronic Renal Insufficiency 86%
  • Genome-Wide Association Study 54%
  • Retrospective Studies 21%

• Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma

  Pilcher, W., Thomas, B. E., Bhasin, S. S., Jayasinghe, R. G., Yao, L., Gonzalez-Kozlova, E., Dasari, S., Kim-Schulze, S., Rahman, A., Patton, J., Fiala, M., Cheloni, G., Kourelis, T., Dhodapkar, M. V., Vij, R., Mehr, S., Hamilton, M., Cho, H. J., Auclair, D., Avigan, D. E., & 4 othersKumar, S. K., Gnjatic, S., Ding, L. & Bhasin, M., Dec 2023, In: npj Genomic Medicine. 8, 1, 3.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • RNA Sequence Analysis 100%
  • Multiple Myeloma 88%
  • B-Lymphoid Precursor Cells 53%
  • Interleukin-16 23%
  • Tumor Microenvironment 15%
  1 Scopus citations

• Dietary Advanced Glycation End Products and Risk of Overall and Cause-Specific Mortality: Results from the Golestan Cohort Study

  Hosseini, E., Mokhtari, Z., Poustchi, H., Khoshnia, M., Dawsey, S. M., Boffetta, P., Abnet, C. C., Kamangar, F., Etemadi, A., Pourshams, A., Sharafkhah, M., Brennan, P., Malekzadeh, R. & Hekmatdoost, A., Mar 2023, In: International Journal of Environmental Research and Public Health. 20, 5, 3788.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Advanced Glycation End-Product 100%
  • Advanced Glycation End Products 85%
  • mortality 59%
  • Hazards 49%
  • Cohort Studies 48%

• Dietary iron restriction protects against vaso-occlusion and organ damage in murine sickle cell disease

  Li, H., Kazmi, J. S., Lee, S., Zhang, D., Gao, X., Maryanovich, M., Torres, L., Verma, D., Kelly, L., Ginzburg, Y. Z., Frenette, P. S. & Manwani, D., 12 Jan 2023, In: Blood. 141, 2, p. 194-199 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Dietary Iron 100%
  • Sickle Cell Anemia 76%
  • Disorder 60%
  • Mutation 59%
  • Iron 58%
  1 Scopus citations

• Discrepancies in estradiol levels in a premenopausal woman receiving abemaciclib despite ovarian function suppression and bilateral salpingo-oophorectomy

  Kessler, A. J., Patel, R., Gallagher, E. J., Shao, T. & Fasano, J., Mar 2023, In: Current Problems in Cancer: Case Reports. 9, 100224.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine 100%
  • Salpingo-oophorectomy 71%
  • Immunoassay 55%
  • Estradiol 48%
  • Aromatase Inhibitors 45%

• Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease

  Lu, H., George, J., Eslam, M., Villanueva, A., Bolondi, L., Reeves, H. L., McCain, M., Chambers, E., Ward, C., Sartika, D., Sands, C., Maslen, L., Lewis, M. R., Ramaswami, R. & Sharma, R., 8 Feb 2023, In: Liver Cancer. 12, 1, p. 19-31 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Fatty Liver 100%
  • Liver Neoplasms 93%
  • Liver Diseases 78%
  • Lipids 27%
  • Area Under Curve 16%

• Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score

  Galsky, M. D., Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Tomita, Y., Nasroulah, F., Li, J., Collette, S., Valderrama, B. P., Grimm, M. O., Appleman, L., Gravis, G., Necchi, A., Ye, D., Stenner, F., Wind-Rotolo, M., Zhang, J. & Ünsal-Kaçmaz, K., 2023, (Accepted/In press) In: European Urology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Survival Analysis 100%
  • Disease-Free Survival 97%
  • Ligands 72%
  • Carcinoma 68%
  • Muscles 62%

• Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant

  Ailawadhi, S., Ogbonnaya, A., Murty, S., Cherepanov, D., Schroader, B. K., Romanus, D., Farrelly, E. & Chari, A., Feb 2023, In: Cancer Medicine. 12, 3, p. 3145-3159 15 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Duration of Therapy 94%
  • Stem Cells 74%
  • Transplants 63%
  • Confidence Intervals 27%

• Effective treatment of low-risk acute GVHD with itacitinib monotherapy

  Etra, A., Capellini, A., Alousi, A., Al Malki, M. M., Choe, H., DeFilipp, Z., Hogan, W. J., Kitko, C. L., Ayuk, F., Baez, J., Gandhi, I., Kasikis, S., Gleich, S., Hexner, E., Hoepting, M., Kapoor, U., Kowalyk, S., Kwon, D., Langston, A., Mielcarek, M., & 10 othersMorales, G., Özbek, U., Qayed, M., Reshef, R., Rösler, W., Spyrou, N., Young, R., Chen, Y. B., Ferrara, J. L. M. & Levine, J. E., 2 Feb 2023, In: Blood. 141, 5, p. 481-489 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Adrenal Cortex Hormone 100%
  • Graft vs Host Disease 82%
  • Adrenal Cortex Hormones 52%
  • P 11 20%
  • Leukopenia 14%
  1 Scopus citations

• Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy

  Katz Sand, I., Gnjatic, S., Krammer, F., Tuballes, K., Carreño, J. M., Satyanarayan, S., Filomena, S., Staker, E., Tcheou, J., Miller, A., Fabian, M., Safi, N., Nichols, J., Patel, J., Krieger, S., Tankou, S., Horng, S., Klineova, S., Beck, E., Merad, M., & 1 othersLublin, F., Feb 2023, In: Multiple Sclerosis and Related Disorders. 70, 104486.

  Research output: Contribution to journal › Article › peer-review

  • Sphingosine 1 Phosphate Receptor Modulators 100%
  • Coronavirus 72%
  • Vaccines 43%
  • Neutralizing Antibodies 41%
  • Severe Acute Respiratory Syndrome 10%

• Germline rare deleterious variant load alters cancer risk, age of onset and tumor characteristics

  Esai Selvan, M., Onel, K., Gnjatic, S., Klein, R. J. & Gümüş, Z. H., Dec 2023, In: npj Precision Oncology. 7, 1, 13.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Age of Onset 100%
  • Neoplasms 34%
  • Genes 15%
  • Whole Exome Sequencing 15%
  • Tumor Burden 12%

• HCC screening with ultrasound: assessment of quality using ultrasound LI-RADS score

  King, M. J., Lee, K. M., Rosberger, S., Huang, H. H., Meza, G. H., Lewis, S. & Taouli, B., Jan 2023, In: Abdominal Radiology. 48, 1, p. 263-270 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Hepatocellular Carcinoma 100%
  • Fibrosis 55%
  • Odds Ratio 47%
  • Ultrasonography 38%
  • Obesity 34%

• IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression

  Lapadula, D., Lam, B., Terai, M., Sugase, T., Tanaka, R., Farias, E., Kadamb, R., Lopez-Anton, M., Heine, C. C., Modasia, B., Aguirre-Ghiso, J. A., Aplin, A. E., Sato, T. & Benovic, J. L., 3 Jan 2023, In: Molecular Cancer Therapeutics. 22, 1, p. 63-74 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Uveal melanoma 100%
  • Therapeutic Uses 62%
  • YM-254890 36%
  • 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 35%
  • mouse insulin-like growth factor-1 17%

• IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases

  Aranda, C. J., Gonzalez-Kozlova, E., Saunders, S. P., Fernandes-Braga, W., Ota, M., Narayanan, S., He, J. S., Del Duca, E., Swaroop, B., Gnjatic, S., Shattner, G., Reibman, J., Soter, N. A., Guttman-Yassky, E. & Curotto de Lafaille, M. A., Mar 2023, In: Allergy: European Journal of Allergy and Clinical Immunology. 78, 3, p. 752-766 15 p.

  Research output: Contribution to journal › Article › peer-review

  • Immunoglobulin E 100%
  • B-Lymphocytes 83%
  • Immunoglobulin G 81%
  • Interleukin-13 30%
  • Plasma Cells 27%

• Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

  Van Oekelen, O., Nath, K., Mouhieddine, T. H., Farzana, T., Aleman, A., Melnekoff, D. T., Ghodke-Puranik, Y., Shah, G. L., Lesokhin, A., Giralt, S., Thibaud, S., Rossi, A., Rodriguez, C., Sanchez, L., Richter, J., Richard, S., Cho, H. J., Chari, A., Usmani, S. Z., Jagannath, S., & 3 othersShah, U. A., Mailankody, S. & Parekh, S., 16 Feb 2023, In: Blood. 141, 7, p. 756-765 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Maturation Antigen 100%
  • Chimeric Antigen Receptors 77%
  • Salvage Therapy 67%
  • Multiple Myeloma 56%
  • Cell- and Tissue-Based Therapy 54%
  1 Scopus citations

• Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

  Gillessen, S., Bossi, A., Davis, I. D., de Bono, J., Fizazi, K., James, N. D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E. S., Aparicio, A. M., Armstrong, A. J., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Blanchard, P., & 98 othersBriganti, A., Bristow, R. G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H. H., Chi, K. N., Chowdhury, S., Clarke, C. S., Clarke, N., Daugaard, G., De Santis, M., Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ngozi Ekeke, O., Evans, C. P., Fanti, S., Feng, F. Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M. S., Horvath, L. G., Hussain, M., Jereczek-Fossa, B. A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P. L., Khauli, R. B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C. J., Mahal, B. A., Maluf, F., Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A. K., Morris, M. J., Mrabti, H., Mukherji, D., Murphy, D. G., Murthy, V., Nguyen, P. L., Oh, W. K., Ost, P., O'Sullivan, J. M., Padhani, A. R., Pezaro, C., Poon, D. M. C., Pritchard, C. C., Rabah, D. M., Rathkopf, D., Reiter, R. E., Rubin, M. A., Ryan, C. J., Saad, F., Pablo Sade, J., Sartor, O. A., Scher, H. I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D. E., Srinivas, S., Sternberg, C. N., Steuber, T., Suzuki, H., Sydes, M. R., Taplin, M. E., Tilki, D., Türkeri, L., Turco, F., Uemura, H., Uemura, H., Ürün, Y., Vale, C. L., van Oort, I., Vapiwala, N., Walz, J., Yamoah, K., Ye, D., Yu, E. Y., Zapatero, A., Zilli, T. & Omlin, A., Mar 2023, In: European Urology. 83, 3, p. 267-293 27 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Prostatic Neoplasms 100%
  • Recurrence 72%
  • Consensus 69%
  • Politics 32%
  • Therapeutics 20%

• Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma

  Richter, J., Lin, P. L., Garcia-Horton, V., Guyot, P., Singh, E., Zhou, Z. Y., Sievert, M. & Taiji, R., 2023, (Accepted/In press) In: Cancer Medicine.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • isatuximab 100%
  • daratumumab 82%
  • carfilzomib 77%
  • Lenalidomide 64%
  • Multiple Myeloma 47%

• Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

  Penter, L., Liu, Y., Wolff, J. O., Yang, L., Taing, L., Jhaveri, A., Southard, J., Patel, M., Cullen, N. M., Pfaff, K. L., Cieri, N., Oliveira, G., Kim-Schulze, S., Ranasinghe, S., Leonard, R., Robertson, T., Morgan, E. A., Chen, H. X., Song, M. H., Thurin, M., & 17 othersLi, S., Rodig, S. J., Cibulskis, C., Gabriel, S., Bachireddy, P., Ritz, J., Streicher, H., Neuberg, D. S., Hodi, F. S., Davids, M. S., Gnjatic, S., Livak, K. J., Altreuter, J., Michor, F., Soiffer, R. J., Garcia, J. S. & Wu, C. J., 2023, (Accepted/In press) In: Blood.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • DNA Methyltransferase Inhibitor 100%
  • Ipilimumab 77%
  • Decitabine 71%
  • Acute Myeloid Leukemia 52%
  • Hematopoietic Stem Cell Transplantation 44%

• Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

  Haber, P. K., Castet, F., Torres-Martin, M., Andreu-Oller, C., Puigvehí, M., Miho, M., Radu, P., Dufour, J. F., Verslype, C., Zimpel, C., Marquardt, J. U., Galle, P. R., Vogel, A., Bathon, M., Meyer, T., Labgaa, I., Digklia, A., Roberts, L. R., Mohamed Ali, M. A., Mínguez, B., & 15 othersCitterio, D., Mazzaferro, V., Finkelmeier, F., Trojan, J., Özdirik, B., Müller, T., Schmelzle, M., Bejjani, A., Sung, M. W., Schwartz, M. E., Finn, R. S., Thung, S., Villanueva, A., Sia, D. & Llovet, J. M., Jan 2023, In: Gastroenterology. 164, 1, p. 72-88.e18

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hepatocellular Carcinoma 100%
  • Interferons 25%
  • Immunotherapy 24%
  • Therapeutics 20%
  • Histocompatibility 17%
  2 Scopus citations

• Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae

  The Mount Sinai COVID-19 Biobank Team, Jan 2023, In: Nature Medicine. 29, 1, p. 236-246 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Coronavirus Infections 100%
  • Severe Acute Respiratory Syndrome 90%
  • Immunoglobulin Genes 88%
  • Transcriptome 64%
  • Molecular Cluster 45%

• Monocytes re-enter the bone marrow during fasting and alter the host response to infection

  Janssen, H., Kahles, F., Liu, D., Downey, J., Koekkoek, L. L., Roudko, V., D'Souza, D., McAlpine, C. S., Halle, L., Poller, W. C., Chan, C. T., He, S., Mindur, J. E., Kiss, M. G., Singh, S., Anzai, A., Iwamoto, Y., Kohler, R. H., Chetal, K., Sadreyev, R. I., & 5 othersWeissleder, R., Kim-Schulze, S., Merad, M., Nahrendorf, M. & Swirski, F. K., 2023, (Accepted/In press) In: Immunity.

  Research output: Contribution to journal › Article › peer-review

  • Monocytes 100%
  • Fasting 96%
  • Bone Marrow 88%
  • Infections 57%
  • Diet 41%

• Outcomes Following SBRT vs. IMRT and 3DCRT for Older Patients with Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm

  Tran, J. H., Mhango, G., Park, H. S., Marshall, D. C., Rosenzweig, K. E., Wang, Q., Wisnivesky, J. P. & Veluswamy, R. R., Jan 2023, In: Clinical Lung Cancer. 24, 1, p. e9-e18

  Research output: Contribution to journal › Article › peer-review

  • Conformal Radiotherapy 100%
  • Intensity-Modulated Radiotherapy 90%
  • Radiosurgery 82%
  • Non-Small Cell Lung Carcinoma 66%
  • Survival 20%

• Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

  Wu, Y. L., van Hyfte, G., Özbek, U., Reincke, M., Gampa, A., Mohamed, Y. I., Nishida, N., Wietharn, B., Amara, S., Lee, P. C., Scheiner, B., Balcar, L., Pinter, M., Vogel, A., Weinmann, A., Saeed, A., Pillai, A., Rimassa, L., Naqash, A. R., Muzaffar, M., & 5 othersHuang, Y. H., Kaseb, A. O., Kudo, M., Pinato, D. J. & Ang, C., 2023, In: Frontiers in Oncology. 13, 1128569.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hepatocellular Carcinoma 100%
  • Progression-Free Survival 90%
  • Survival 68%
  • Odds Ratio 63%
  • Portal Hypertension 54%

• Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study

  Cohen, A. D., Hari, P., Htut, M., Berdeja, J. G., Usmani, S. Z., Madduri, D., Olyslager, Y., Goldberg, J. D., Schecter, J. M., Jackson, C. C., Gries, K. S., Fastenau, J. M., Valluri, S., Deraedt, W., Akram, M., Crawford, R., Morrison, R., Doward, L., Morgan, K., Seldam, S. T., & 2 othersJakubowiak, A. & Jagannath, S., Jan 2023, In: Clinical Lymphoma, Myeloma and Leukemia. 23, 1, p. 68-77 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Interviews 67%
  • Motivation 32%
  • Quality of Life 19%
  • Pain 17%

• Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

  Kuruvilla, J., Armand, P., Hamadani, M., Kline, J., Moskowitz, C. H., Avigan, D., Brody, J. D., Ribrag, V., Herrera, A. F., Morschhauser, F., Kanate, A., Zinzani, P. L., Bitran, J., Ghesquieres, H., Schuster, S. J., Farooqui, M., Marinello, P. & Bartlett, N. L., 2023, In: Leukemia and Lymphoma. 64, 1, p. 130-139 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • pembrolizumab 100%
  • Non-Hodgkin's Lymphoma 67%
  • Cell Transplantation 38%
  • Lenalidomide 23%
  • Safety 20%

• Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission

  Manning-Geist, B. L., Gnjatic, S., Aghajanian, C., Konner, J., Kim, S. H., Sarasohn, D., Soldan, K., Tew, W. P., Sarlis, N. J., Zamarin, D., Kravetz, S., Laface, I., Rasalan-Ho, T., Qi, J., Wong, P., Sabbatini, P. J. & O’Cearbhaill, R. E., Mar 2023, In: Cancers. 15, 5, 1458.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nivolumab 100%
  • Subunit Vaccines 88%
  • Wilms Tumor 88%
  • Ovarian Neoplasms 66%
  • Progression-Free Survival 33%

• Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study

  Putta, S., Young, B. A., Levine, J. E., Reshef, R., Nakamura, R., Strouse, C., Perales, M. A., Howard, A., Pine, P., Shi, J., Zhang, P., Ho, V. T. & Saber, W., Mar 2023, In: Transplantation and Cellular Therapy. 29, 3, p. 166.e1-166.e10

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hepatic Veno-Occlusive Disease 100%
  • Cell Transplantation 69%
  • Allogeneic Cells 69%
  • Bone Marrow 47%
  • Clinical Trials 42%

• Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study

  Talbot, T., D'Alessio, A., Pinter, M., Balcar, L., Scheiner, B., Marron, T. U., Jun, T., Dharmapuri, S., Ang, C., Saeed, A., Hildebrand, H., Muzaffar, M., Fulgenzi, C. A. M., Amara, S., Naqash, A. R., Gampa, A., Pillai, A., Wang, Y., Khan, U., Lee, P. C., & 16 othersHuang, Y. H., Bengsch, B., Bettinger, D., Mohamed, Y. I., Kaseb, A., Pressiani, T., Personeni, N., Rimassa, L., Nishida, N., Kudo, M., Weinmann, A., Galle, P. R., Muhammed, A., Cortellini, A., Vogel, A. & Pinato, D. J., Mar 2023, In: Liver International. 43, 3, p. 695-707 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hepatocellular Carcinoma 100%
  • Disease Progression 99%
  • Observational Studies 96%
  • Survival 49%
  • Protein-Tyrosine Kinases 48%
  1 Scopus citations

• Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

  Thompson, M. A., Boccadoro, M., Leleu, X., Vela-Ojeda, J., van Rhee, F., Weisel, K. C., Rifkin, R. M., Usmani, S. Z., Hájek, R., Cook, G., Abonour, R., Armour, M., Morgan, K. E., Yeh, S. P., Costello, C. L., Berdeja, J. G., Davies, F. E., Zonder, J. A., Lee, H. C., Omel, J., & 9 othersSpencer, A., Terpos, E., Hungria, V. T. M., Puig, N., Fu, C., Ferrari, R. H., Ren, K., Stull, D. M. & Chari, A., Mar 2023, In: Clinical Lymphoma, Myeloma and Leukemia. 23, 3, p. e171-e181

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Human Influenza 93%
  • Vaccination 80%
  • Survival 56%
  • Health Resources 15%

• Single-cell profiling of ineffective erythropoiesis in a mouse model of β-thalassaemia intermedia

  Peng, Y., Liang, L., Zhang, H., Liu, H., Zhang, G., Sun, S., Guo, X., Wang, Y., Hu, B., Liu, R., Li, Y., Nie, L., Zhang, J., Ye, M., Ginzburg, Y. Z., Lin, Z., Yin, B., Chen, H. & Liu, J., 2023, (Accepted/In press) In: British Journal of Haematology.

  Research output: Contribution to journal › Article › peer-review

  • Erythropoiesis 100%
  • beta-Thalassemia 99%
  • Iron 42%
  • HSP70 Heat-Shock Proteins 42%
  • Reticulocytes 41%

• Standard Naloxone Prescribing for Palliative Care Cancer Patients on Opioid Therapy: A Single-Site Quality Improvement Pilot to Assess Attitudes and Access

  Afezolli, D., Flemig, D., Easton, E., Austin, V., Scarborough, B. & Smith, C. B., 2023, (Accepted/In press) In: Journal of Pain and Symptom Management.

  Research output: Contribution to journal › Article › peer-review

  • Naloxone 100%
  • Quality Improvement 91%
  • Palliative Care 90%
  • Opioid Analgesics 83%
  • Neoplasms 30%

• Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials

  Chhabra, S., Callander, N., Watts, N. L., Costa, L. J., Thapa, B., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Anderson, L. D., Bal, S., Dhakal, B., Nathwani, N., Shah, N., Medvedova, E., Bumma, N., Holstein, S. A., & 17 othersCostello, C., Jakubowiak, A., Wildes, T. M., Schmidt, T., Orlowski, R. Z., Shain, K. H., Cowan, A. J., Dholaria, B., Cornell, R. F., Jerkins, J. H., Pei, H., Cortoos, A., Patel, S., Lin, T. S., Usmani, S. Z., Richardson, P. G. & Voorhees, P. M., Mar 2023, In: Transplantation and Cellular Therapy. 29, 3, p. 174.e1-174.e10

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • daratumumab 100%
  • Quadruplets 99%
  • Hematopoietic Stem Cell Mobilization 82%
  • Lenalidomide 78%
  • Multiple Myeloma 58%

• Time to pain relief: A randomized controlled trial in the emergency department during vaso-occlusive episodes in sickle cell disease

  Tanabe, P., Bosworth, H. B., Crawford, R. D., Glassberg, J., Miller, C. N., Paice, J. A. & Silva, S., 2023, (Accepted/In press) In: European Journal of Haematology.

  Research output: Contribution to journal › Article › peer-review

  • Sickle Cell Anemia 100%
  • Hospital Emergency Service 73%
  • Randomized Controlled Trials 61%
  • Pain 52%
  • Weights and Measures 14%

• Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry

  Lee, H. C., Ramasamy, K., Weisel, K., Abonour, R., Hardin, J. W., Rifkin, R. M., Ailawadhi, S., Terebelo, H. R., Durie, B. G. M., Tang, D., Joshi, P., Liu, L., Jou, Y. M., Che, M., Hernandez, G., Narang, M., Toomey, K., Gasparetto, C., Wagner, L. I. & Jagannath, S., Feb 2023, In: Clinical Lymphoma, Myeloma and Leukemia. 23, 2, p. 112-122 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Quality of Health Care 87%
  • Registries 80%
  • Quality of Life 65%
  • Survival 56%
• 2022

  4D flow MRI in abdominal vessels: prospective comparison of k-t accelerated free breathing acquisition to standard respiratory navigator gated acquisition

  Bane, O., Stocker, D., Kennedy, P., Hectors, S. J., Bollache, E., Schnell, S., Schiano, T., Thung, S., Fischman, A., Markl, M. & Taouli, B., Dec 2022, In: Scientific Reports. 12, 1, 19886.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Respiration 100%
  • Acceleration 78%
  • Splenic Vein 56%
  • Splenic Artery 53%
  • Hepatic Artery 46%

• ABCL-439 Subcutaneous Epcoritamab With Gemcitabine + Oxaliplatin (GemOx) Induced High Response Rates in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Autologous Stem Cell Transplant (ASCT)

  Brody, J., Wahlin, B. E., Phillips, T., Costello, R., Lugtenburg, P., Cordoba, R., Wang, L., Wu, J., Elliott, B., Abbas, A. & J⊘rgensen, J., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S379-S380

  Research output: Contribution to journal › Article › peer-review

  • Oxaliplatin 100%
  • Lymphoma, Large B-Cell, Diffuse 95%
  • gemcitabine 94%
  • Stem Cells 62%
  • Transplants 53%

• ABCL-452 First-Line Treatment With Subcutaneous Epcoritamab + R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update

  Falchi, L., Offner, F., Belada, D., Brody, J., Linton, K. M., Karimi, Y., Cordoba, R., Snauwaert, S., Abbas, A., Wang, L., Wu, J., Elliott, B. & Clausen, M. R., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S380

  Research output: Contribution to journal › Article › peer-review

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Therapeutics 14%
  • tocilizumab 8%
  • Bispecific Antibodies 8%
  • Injection Site Reaction 8%

• Acute myeloid leukemia with an MN1-ETV6 fusion in a young child with Down syndrome

  Rosenzweig, J., Pillai, P. M., Prockop, S., Benayed, R., Brodersen, L. E., Najfeld, V., Loken, M. R., Zhang, Y. & Shukla, N., Apr 2022, In: Cold Spring Harbor molecular case studies. 8, 3, a006167.

  Research output: Contribution to journal › Article › peer-review

  • Myeloid Leukemia 100%
  • Down Syndrome 85%
  • Acute Myeloid Leukemia 77%
  • Mutation 69%
  • Cytogenetics 57%

• Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring

  Martini, A., Yu, M., Raggi, D., Joshi, H., Fallara, G., Montorsi, F., Necchi, A. & Galsky, M. D., 1 Aug 2022, In: Cancer. 128, 15, p. 2892-2897 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Disease-Free Survival 100%
  • Immunotherapy 93%
  • Carcinoma 70%
  • Muscles 63%
  • Observation 56%
  2 Scopus citations

• Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children’s Oncology Group experience

  Andolina, J. R., Wang, Y. C., Ji, L., Freyer, D. R., Levine, J. E., Pulsipher, M. A., Gamis, A. S., Aplenc, R., Roth, M. E., Harrison, L. & Cairo, M. S., Mar 2022, In: Bone Marrow Transplantation. 57, 3, p. 445-452 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Unrelated Donors 100%
  • Stem Cell Transplantation 83%
  • Leukemia 65%
  • Young Adult 64%
  • Pediatrics 51%

• Age alters the oncogenic trajectory toward luminal mammary tumors that activate unfolded proteins responses

  Jenkins, E. C., Chattopadhyay, M., Gomez, M., Torre, D., Ma'ayan, A., Torres-Martin, M., Sia, D. & Germain, D., Oct 2022, In: Aging Cell. 21, 10, e13665.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Unfolded Protein Response 100%
  • Estrogen Receptor alpha 93%
  • Breast Neoplasms 51%
  • Genes 12%
  • Endoplasmic Reticulum 9%

• A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma

  Zhou, R. W., Xu, J., Martin, T. C., Zachem, A. L., He, J., Ozturk, S., Demircioglu, D., Bansal, A., Trotta, A. P., Giotti, B., Gryder, B., Shen, Y., Wu, X., Carcamo, S., Bosch, K., Hopkins, B., Tsankov, A., Steinhagen, R., Jones, D. R., Asara, J., & 7 othersChipuk, J. E., Brody, R., Itzkowitz, S., Chio, I. I. C., Hasson, D., Bernstein, E. & Parsons, R. E., Dec 2022, In: Nature Communications. 13, 1, 6041.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pentose Phosphate 100%
  • Oncogenic 98%
  • Enhancer 83%
  • Tumor Microenvironment 73%
  • tumors 67%

• Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma

  Carcamo, S., Nguyen, C. B., Grossi, E., Filipescu, D., Alpsoy, A., Dhiman, A., Sun, D., Narang, S., Imig, J., Martin, T. C., Parsons, R., Aifantis, I., Tsirigos, A., Aguirre-Ghiso, J. A., Dykhuizen, E. C., Hasson, D. & Bernstein, E., 5 Apr 2022, In: Cell Reports. 39, 1, 110637.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Enhancer 100%
  • Chromatin 74%
  • Melanoma 70%
  • Transcription Factors 63%
  • Gene Expression 25%
  4 Scopus citations